Scientific References – Publications
QPS Neuropharmacology
QPS encourages its scientists to publish and disseminate the results of their high quality research which is mostly done in close collaboration with our clients.
The following articles are hyperlinked to the original journal article or an abstract of the article:
Alzheimer’s Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits
Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T 3rd, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H 3rd, Catalano SM.
PLoS One. 2014 Nov 12;9(11):e111898. doi: 10.1371/journal.pone.0111898.
Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivo model of Alzheimer’s disease
Tina Löffler, Stefanie Flunkert, Daniel Havas, Cornelia Schweinzer, Marni Uger, Manfred Windisch, Ernst Steyrer, Birgit Hutter-Paier.
Journal of Neuroinflammation. DOI: 10.1186/1742-2094-11-84 (May, 2014)
Tracking of Magnetite Labeled Nanoparticles in the Rat Brain Using MRI
Naira P. Martínez Vera, Reinhold Schmidt, Klaus Langer, Iavor Zlatev, Robert Wronski, Ewald Auer, Daniel Havas, Manfred Windisch, Hagen von Briesen, Sylvia Wagner, Julia Stab, Motti Deutsch, Claus Pietrzik, Franz Fazekas, Stefan Ropele
PLoS One. March 14, 2014.
Increased Efflux of Amyloid-β Peptides through the Blood-Brain Barrier by Muscarinic Acetylcholine Receptor Inhibition Reduces Pathological Phenotypes in Mouse Models of Brain Amyloidosis.
Paganetti P, Antoniello K, Devraj K, Toni N, Kieran D, Madani R, Pihlgren M, Adolfsson O, Froestl W, Schrattenholz A, Liebner S, Havas D, Windisch M, Cirrito JR, Pfeifer A, Muhs A.
J Alzheimers Dis. 2013 Sep 26.
The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon.
Rosini M, Simoni E, Bartolini M, Soriano E, Marco-Contelles J, Andrisano V, Monti B, Windisch M, Hutter-Paier B, McClymont DW, Mellor IR, Bolognesi ML.
ChemMedChem. 2013 Aug;8(8):1276-81. doi: 10.1002/cmdc.201300263. Epub 2013 Jul 3.
Commentary to the recently published review “Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer’s disease” by Li, Evrahimi and Schluesener. Ageing Res. Rev. 2013 Jan;12(1):116-40.
Windisch M, Flunkert S, Havas D, Hutter-Paier B.
Ageing Res Rev. 2013 Jul 10;12(4):852-854. doi: 10.1016/j.arr.2013.06.006.
CSF biomarker variability in the Alzheimer’s Association quality control program.
Alzheimer’s Association QC Program Work Group (QPS Austria GmbH collaborator: Duller S.)
Alzheimers Dement. 2013 May;9(3):251-61. doi: 10.1016/j.jalz.2013.01.010.
Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice.
Löffler T, Flunkert S, Havas D, Sántha M, Hutter-Paier B, Steyrer E, Windisch M.
Neurobiol Aging. 2013 May 2
Non-selective calcium channel blocker bepridil decreases secondary pathology in mice after photothrombotic cortical lesion.
Lipsanen A, Flunkert S, Kuptsova K, Hiltunen M, Windisch M, Hutter-Paier B, Jolkkonen J.
PLoS One. 2013;8(3):e60235. doi: 10.1371/journal.pone.0060235. Epub 2013 Mar 26.
CaV1.2 calcium channel expression in reactive astrocytes is associated with the formation of amyloid-β plaques in an Alzheimer’s disease mouse model.
LDaschil N, Obermair GJ, Flucher BE, Stefanova N, Hutter-Paier B, Windisch M, Humpel C, Marksteiner J.
J Alzheimers Dis. 2013;37(2):439-51. doi: 10.3233/JAD-130560.
